Argenx
ARGX
#483
Rank
C$73.61 B
Marketcap
C$1,171
Share price
-0.67%
Change (1 day)
4.58%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): C$22.07

According to Argenx 's latest financial reports the company's current EPS (TTM) is C$22.58. In 2025 the company made an earnings per share (EPS) of C$30.11 an increase over its 2024 EPS that were of C$19.88.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$22.07-26.7%
2025C$30.1151.44%
2024C$19.88-369.77%
2023C-$7.37-60.46%
2022C-$18.6463.33%
2021C-$11.41-40.37%
2020C-$19.14183.47%
2019C-$6.75123.09%
2018C-$3.0354.93%
2017C-$1.9514.07%
2016C-$1.7113.05%
2015C-$1.51-36.34%
2014C-$2.38209.04%
2013C-$0.77-33.99%
2012C-$1.17185.59%
2011C-$0.41